Related Experiment Videos
Immunohistochemistry and DNA flow cytometry in soft-tissue sarcomas
1Department of Histopathology, St. Thomas's Hospital (UMDS), London, England.
Hematology/Oncology Clinics of North America
|June 1, 1995
Summary
Immunohistochemistry aids soft tissue sarcoma diagnosis but offers limited value for typing. Proliferation markers and genetic analysis show poor correlation with clinical outcomes in these tumors.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Immunohistochemistry is crucial for soft tissue sarcoma diagnosis and classification alongside light microscopy.
- Accurate histologic typing by experienced pathologists remains the cornerstone of diagnosis.
Purpose of the Study:
- To evaluate the added value of immunohistochemistry, proliferation markers, tumor suppressor genes, oncogene products, and DNA flow cytometry in soft tissue sarcoma diagnosis and prognosis.
- To determine the correlation between these markers and clinical outcomes.
Main Methods:
- Immunohistochemical analysis of proliferation markers.
- Immunohistochemical assessment of tumor suppressor genes and oncogene products.
- DNA flow cytometry for ploidy and cell proliferation analysis.
Main Results:
- Immunohistochemical analysis of proliferation markers provides minimal additional benefit to experienced histologic typing.
- Assessment of tumor suppressor genes and oncogene products offers pathogenetic insights but lacks reliable clinical outcome correlation.
- DNA flow cytometry for ploidy analysis does not differentiate benign from malignant lesions.
- Cell proliferation assessment by DNA flow cytometry does not accurately predict clinical behavior.
Conclusions:
- While immunohistochemistry is vital for soft tissue sarcoma diagnosis, its role in refining histologic typing and predicting clinical outcomes is limited.
- Current immunohistochemical and DNA flow cytometry methods for assessing proliferation and genetic markers do not reliably correlate with patient prognosis.